Segment Information

6 Months Ended

Jun. 30, 2011

Segment Information

Note 11 – Segment Information

The Company’s financial information broken down by reportable segment was as follows (in thousands):

	Three Months Ended June 30,							Six Months Ended June 30,
	2011				2010			2011			2010
Revenues
Pharmaceutical Manufacturing - China	$	16,151.2			$	19,369.7		$	34,292.9		$	35,144.2
Cell Therapy - United States		2,210.8				37.8			3,660.0			96.5
Regenerative Medicine - China		98.7				-			148.9			-
	$	18,460.7			$	19,407.5		$	38,101.8		$	35,240.7
Loss from operations
Pharmaceutical Manufacturing - China	$	642.6			$	3,559.0		$	2,762.2		$	6,749.7
Cell Therapy - United States		(2,937.2	)			(3,042.4	)		(6,977.7	)		(4,612.5	)
Regenerative Medicine - China		(435.2	)			(423.4	)		(1,165.3	)		(736.9	)
Corporate office		(7,288.7	)			(3,596.1	)		(12,629.4	)		(7,511.5	)
	$	(10,018.5	)		$	(3,502.9	)	$	(18,010.2	)	$	(6,111.2	)
Total assets	June 30, 2011			December 31, 2010
Pharmaceutical Manufacturing - China	$	127,547.7			$	125,133.7
Cell Therapy - United States		34,810.9				1,241.2
Regenerative Medicine - China		3,471.1				5,032.9
Corporate office		4,502.7				11,616.9
	$	170,332.4			$	143,024.7